## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($96.09)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Aggressive lymphoma trial: tafasitamab combo meets key survival goals**
- Source: Stock Titan | 20260105T123236 | Bullish | Relevance: 100%
- Incyte announced positive topline results from its pivotal Phase 3 frontMIND trial, showing that tafasitamab and lenalidomide combined with R-CHOP met the primary endpoint of progression-free survival in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). The trial also achieved its key secondary endpoint of event-free survival, with no new safety signals observed. These results indicate a potential new treatment option for high-risk DLBCL patients, leading Incyte to plan a supplemental Biologics License Application filing in the first half of 2026.

**2. Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com**
- Source: Investing.com Australia | 20260105T130823 | Bullish | Relevance: 100%
- Incyte (NASDAQ:INCY) announced that its Phase 3 frontMIND trial for tafasitamab in first-line diffuse large B-cell lymphoma (DLBCL) treatment met its primary endpoint of progression-free survival. The trial also achieved its key secondary endpoint of event-free survival with no new safety signals. Incyte plans to submit a supplemental Biologics License Application for tafasitamab in first-line DLBCL treatment in the first half of 2026.

**3. Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com**
- Source: Investing.com UK | 20260105T120816 | Bullish | Relevance: 100%
- Incyte announced its Phase 3 frontMIND trial for tafasitamab in combination with lenalidomide and R-CHOP for first-line diffuse large B-cell lymphoma (DLBCL) treatment met its primary endpoint of progression-free survival. The company plans to file a supplemental Biologics License Application in the first half of 2026 based on these positive results. This news follows Incyte's recent European Commission approval for Minjuvi in relapsed or refractory follicular lymphoma, and analyst firms have maintained their ratings on the company.

**4. Financiere des Professionnels Fonds d investissement inc. Invests $1.48 Million in Incyte Corporation $INCY**
- Source: MarketBeat | 20260104T113609 | Somewhat-Bullish | Relevance: 100%
- Financiere des Professionnels Fonds d’investissement inc. has acquired a new stake of 17,486 shares in Incyte Corporation, valued at approximately $1.48 million, during the third quarter. Despite several firms raising their price targets for Incyte, the consensus analytical rating remains "Hold" with an average price target of $99.79. Institutional investors hold a substantial 96.97% of Incyte's stock, while corporate insiders have been net sellers in the last 90 days.

**5. Is Incyte the Sleeper Stock About To Blow Up? Real Talk On This Quiet Biotech Beast**
- Source: AD HOC NEWS | 20260103T150816 | Bullish | Relevance: 100%
- Incyte is presented as a quietly performing biotech company with a strong cash position and a promising drug pipeline, contrasting with the current hype around AI and meme stocks. The article evaluates Incyte's flagship product, pipeline potential, and financial health, ultimately suggesting it could be a long-game winner for investors willing to look beyond immediate viral trends. While it lacks the mainstream "clout" of competitors like Vertex Pharmaceuticals, its solid fundamentals and under-the-radar status might make it an attractive pick for strategic investors.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 18 ($30.49M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $30M sold (18 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +20%) could attract flows.
- Momentum building: MRS_20 improving +3.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Forward P/E 13.3x attractive for 14% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (3 raises, avg +20%). Insider selling cluster ($30.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.0B |
| Beta | 0.82 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 7.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 13.3 |
| Current P/E | 15.1 |
| YoY Growth | 13.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -0.2% to 2.8% (+3.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.2pp (needs >4.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.84% (CS: 72) | Neutral |
| RSI_14 | 56.4 | Neutral |
| MACD Histogram | 0.22 | Bullish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.015x | Above |
| vs SMA200 | 1.283x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $101.79
- **Stop Loss:** $96.09 (5.6% risk)
- **Target:** $113.19 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 151
- **Position Value:** $15,370.29
- **Portfolio %:** 15.37%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*